Interim Results 2018

Interim Results 2018

Sinclair Pharma plc (SPH.L), (“Sinclair”, or the “Group”, or the “Company”) the international aesthetics company, today announces its unaudited interim results for the six months ended 30 June 2018.

Download Presentation (PDF)

Revenue £21.3 million, headline growth of 6% with Ex-US revenues up 18% at constant currency.

Highlights

Post Period Highlights

 I am pleased with the performance of the Group in the first half of 2018 which has seen a consolidation of our direct presence in several key markets. Much was achieved during the period and the Group continues to see strong demand for its products. Sinclair is well placed to deliver strong second half sales, particularly in leading markets Brazil, South Korea and the US, and underpinned more generally by a growing global aesthetics market. Trading since the end of the interim period has shown significant growth over the same period in 2017. We remain confident of delivering strong sales growth for the full year ending 31 December 2018. 

Chris Spooner, CEO
Download complete Presentation

*Adjusted EBITDA defined as earnings before interest, tax, depreciation, amortisation, impairment, share-based payments, exceptional items and loss from discontinued operations.

Share this post:

Sinclair Network

At Sinclair we strive to provide the highest standards of training and ongoing support, working in partnership with our physician customers to deliver patients unparalleled clinical results and industry leading safety standards.